8-K: Moleculin Launches Pancreatic Cancer Study

Moleculin Biotech announced a new investigator-initiated Phase 1B/2 study of Annamycin for third-line advanced pancreatic cancer with Atlantic Health.

Summary

• Moleculin Biotech, Inc. is collaborating with Atlantic Health on an investigator-initiated Phase 1B/2 single-arm study.
• The study will evaluate Annamycin for third-line (3L) treatment of advanced pancreatic cancer.
• Pancreatic cancer has the highest mortality rate globally and is the seventh leading cause of cancer death.
• Preclinical studies suggest Annamycin targets critical factors in pancreatic cancer and associated liver metastases.
• Annamycin demonstrates high affinity for and ability to concentrate in the pancreas.
• Upregulation of topoisomerase II, Annamycin's primary target, correlates with poor survival in pancreatic cancer patients.
• Annamycin lacks cardiotoxicity, potentially enabling its use in chronic or maintenance therapies.
• Moleculin will supply Annamycin and manage the Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA).
• Atlantic Health, specifically Dr. Angela Alistar, MD, will be responsible for conducting the Phase 1B/2 study.
• Moleculin estimates an additional cost of approximately $1 million from 2026 into 2030 for drug supply and outside laboratory testing for this trial.

Sentiment

Score: 8

Explanation: The announcement of a new clinical study for a challenging cancer with a reputable partner, coupled with promising preclinical data and unique drug properties, is a strong positive. The explicit mention of significant future financing needs without commitments introduces a notable risk, but the overall news is favorable for drug development.

Positives

• Initiation of a new Phase 1B/2 clinical study for Annamycin in a challenging indication (pancreatic cancer).
• Collaboration with Atlantic Health, a leading healthcare provider, which is funding and conducting the study.
• Compelling preclinical data showing high activity of Annamycin against pancreatic cancer and liver metastases.
• Annamycin's demonstrated high affinity for and ability to concentrate in the pancreas, addressing a key challenge for existing therapies.
• Validation of Annamycin's target, topoisomerase II, which is highly correlated with poor survival in pancreatic cancer.
• Annamycin's lack of cardiotoxicity, potentially allowing for chronic or maintenance therapies, a significant advantage over other anthracyclines.
• Annamycin already holds Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, and Orphan Drug Designation for STS lung mets and R/R AML from the EMA.
• The study further bolsters efforts to advance Annamycin through multiple investigator-initiated studies.

Negatives

• Pancreatic cancer remains one of the most devastating and difficult-to-treat malignancies with limited options, especially in the third-line setting where no approved standard of care exists.
• Moleculin will require significant additional financing to conduct its clinical trials, for which the Company has no current commitments.
• The estimated cost of $1 million for this specific trial is an additional expenditure for the company.

Risks

• The timing of the commencement of the investigator-initiated clinical trial described is a forward-looking statement and subject to uncertainties.
• Moleculin will require significant additional financing to conduct its clinical trials as described, and the Company has no commitments for such financing.
• The achievement of milestones described assumes the Company's ability to secure financing on a timely basis.
• Expectations reflected in forward-looking statements may prove to be materially different from actual results.
• Known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. Risk Factors in the most recently filed Form 10-K and updated in Form 10-Q filings.

Future Outlook

Moleculin believes Annamycin is a highly promising candidate for patients with significant unmet needs like pancreatic cancer. The company continues to advance Annamycin through multiple investigator-initiated studies. The timing of the commencement of the investigator-initiated clinical trial is a forward-looking statement. The company will require significant additional financing to conduct its clinical trials, and milestones assume the ability to secure such financing on a timely basis.

Management Comments

• "We are excited to work with Atlantic Health to advance the development of Annamycin for the treatment of pancreatic cancer." Walter Klemp, Chairman and CEO of Moleculin.
• "Their interest in funding and conducting this study stems from the compelling preclinical data presented at several American Association for Cancer Research conferences showing a high level of activity by Annamycin against pancreatic cancer and associated liver metastases in preclinical studies." Walter Klemp.
• "We believe this may be related to Annamycin’s demonstrated high affinity for and ability to concentrate in the pancreas, especially considering the well-documented challenge of achieving adequate drug uptake to the pancreas with existing therapies." Walter Klemp.
• "Recent published data now reveal that the upregulation of topoisomerase II, the primary target of Annamycin, is highly correlated with poor survival in pancreatic cancer patients, so we have a highly validated target with pancreatic cancer." Walter Klemp.
• "Coupled with Annamycin’s demonstrated lack of cardiotoxicity, which could enable, for the first time ever, the use of an anthracycline in chronic or maintenance therapies, we believe pancreatic cancer could be an important additional opportunity for Annamycin." Walter Klemp.
• "This study further bolsters our efforts to advance and develop Annamycin through multiple investigator-initiated studies to unlock its potential as a treatment option for many other types of cancers." Walter Klemp.
• "We continue to be encouraged by the preliminary preclinical data seen to date and believe Annamycin is a highly promising candidate for patients where there remains significant unmet need, such as pancreatic cancer." Walter Klemp.
• "Pancreatic cancer remains one of the most devastating and difficult-to-treat malignancies, with limited options once patients progress beyond firstand second-line therapy." Dr. Angela Alistar, MD, Atlantic Health.
• "In particular, for the treatment options in the third-line setting, where survival rates are poor, no approved standard of care exists." Dr. Angela Alistar.
• "Based on the consistent safety and efficacy data, both clinically and preclinically, seen with Annamycin across a broad range of cancers, we believe this represents a great opportunity to address this high unmet need." Dr. Angela Alistar.

Industry Context

Pancreatic cancer is a highly aggressive malignancy with a very high mortality rate and limited treatment options, especially in advanced stages and for third-line therapy where no approved standard of care exists. The development of novel therapies like Annamycin, particularly those addressing drug uptake challenges and cardiotoxicity, represents a significant advancement in a field with substantial unmet medical need. Annamycin's targeting of topoisomerase II, which is correlated with poor survival, aligns with current oncology research focusing on specific molecular pathways.

Comparison to Industry Standards

• Annamycin's demonstrated lack of cardiotoxicity is a significant advantage compared to currently prescribed anthracyclines, which are often limited by cardiac side effects, preventing their use in chronic or maintenance therapies.
• The challenge of achieving adequate drug uptake to the pancreas with existing therapies is a well-documented issue, which Annamycin's high affinity for and ability to concentrate in the pancreas aims to overcome.
• The absence of an approved standard of care for third-line advanced pancreatic cancer highlights a critical gap in current treatment paradigms, positioning Annamycin to potentially fill this void if successful.

Stakeholder Impact

• Shareholders: Potential for increased value if Annamycin proves successful in pancreatic cancer, expanding its market potential. However, dilution risk due to future financing needs.
• Patients: Offers a potential new therapeutic option for advanced pancreatic cancer, a disease with high unmet need and poor prognosis, especially in the third-line setting.
• Medical Community: Provides new clinical data and research into a difficult-to-treat cancer, potentially advancing treatment paradigms.
• Employees: Continued development and expansion of the drug pipeline could lead to job stability and growth opportunities.

Next Steps

• Atlantic Health to conduct the Phase 1B/2 study of Annamycin for pancreatic cancer.
• Moleculin to supply Annamycin and maintain the IND with the FDA for the pancreatic cancer study.
• Moleculin continues its pivotal Phase 2B/3 MIRACLE trial (MB-108) for R/R AML.
• Moleculin needs to secure significant additional financing to conduct its clinical trials.

Key Dates

Recommendation

The initiation of a new investigator-initiated Phase 1B/2 study for Annamycin in advanced pancreatic cancer, a disease with a high unmet medical need and no approved third-line standard of care, is a significant positive development. The collaboration with Atlantic Health, which is funding and conducting the study, reduces Moleculin's direct operational burden. Compelling preclinical data, Annamycin's unique properties (pancreatic concentration, lack of cardiotoxicity), and its validated target (topoisomerase II) suggest strong therapeutic potential. While the need for future financing is a risk, the expansion of Annamycin's clinical development into a new, high-value indication, building on existing Fast Track and Orphan Drug designations, significantly enhances the company's long-term prospects and de-risks the overall pipeline. This news represents a material step forward in the company's drug development efforts.

Keywords

Annamycin, pancreatic cancer, Moleculin Biotech, MBRX, clinical trial, Phase 1B/2, oncology, anthracycline, topoisomerase II, Atlantic Health, cancer treatment, drug development, IND, FDA, Orphan Drug Designation, Fast Track Status